Category: hemp

Medical Marijuana, Inc. Subsidiary Kannaway® Announces Exclusive Roadshow Event in Orange County, CA

SHARE THIS POST SAN DIEGO, Jan. 11, 2018 — Medical Marijuana, Inc.(OTC:MJNA) announced today that its subsidiary Kannaway LLC, the first hemp lifestyle network to offer cannabidiol (CBD) hemp botanical products, is holding an exclusive Roadshow Event in Orange County, CA, this Saturday. The Roadshow Event provides a unique opportunity to meet with top Kannaway® leaders, the Company’s executive team and fellow Kannaway® business owners. Attendees will hear from executive team members, including Kannaway® CEO Blake Schroeder, President Brad Tayles and CEO of Kannaway® parent company Medical Marijuana, Inc. Dr. Stuart Titus. “Attending one of our Roadshow events is the best way to discover what it takes to become a Kannaway trailblazer from other successful Brand Ambassadors and to learn about the vast opportunities given by being part of the Kannaway business,” said Kannaway® CEO Blake Schroeder. “This is an exciting time to be a part of Kannaway. The company has recently expanded to Europe and has plans to enter many more new markets in 2018,” Schroeder continued. “In addition, Kannaway had its largest revenue year in company history in 2017, experiencing year-over-year revenue growth of more than 255% compared to 2016.” The Orange County Roadshow Event in Newport Beach, CA, is scheduled from 1-4 p.m. on Saturday, Jan. 13, at the Hyatt Regency. Advance tickets are available now for just $30, the price of tickets will increase to $40 at the door....

Read More

Global Hemp Group and Marijuana Company of America Issue Final Report on New Brunswick Hemp/CBD Project

SHARE THIS POST Vancouver, British Columbia – January 10, 2018 – GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE:GHG / FF:GHG / OTC:GBHPF) and Marijuana Company of America, Inc. (“MCOA”) (OTC: MCOA), industrial hemp and cannabis corporations, are pleased to provide a final report on the first phase of their industrial hemp project in New Brunswick. On September 5, 2017, MCOA and GHG announced their joint venture to develop commercial hemp production on the Acadian peninsula of New Brunswick, Canada. In this first phase of GHG and MCOA’s (the “Partners”) multi-phase hemp project in northeast New Brunswick (NB), the Partners have successfully cultivated industrial hemp during the 2017 growing season (see Phase One Hemp Trial Results below). For this phase of the project, the Partners only grew hemp for research purposes, as this was the first time in 20 years that industrial hemp was grown in the region. The objective of phase one was to re-introduce hemp into the area, and ensure that it could be productive under New Brunswick growing conditions prior to significantly increasing cultivation acreage and building a hemp processing facility in the region, in future phases of the project. The Partners are preparing for the proposed changes to Canadian legislation expected in 2018 that will permit cannabidiol (CBD) extraction from industrial hemp. Health Canada is currently consulting industry representatives regarding the regulations that will accompany...

Read More

Medical Marijuana, Inc. Announces Historic Registration of its CBD Products in Paraguay as a Medicine

SHARE THIS POST Official Product Registration Makes Medical Marijuana, Inc. Cannabis Products First Available Through Medical Distribution Channels in Paraguay SAN DIEGO, Jan. 9, 2018 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced the historic registration of its Real Scientific Hemp Oil-X™ (RSHO-X™) and RSHO™-Blue Label products as registered medicines by Paraguay’s national health regulation organization (Dirección Nacional de Vigilancia Sanitaria). “We are a Company of firsts and we are excited about this new historic milestone of being the first company to have a CBD product registered in Paraguay,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We have actively pursued getting our pipeline of botanical cannabis products registered and approved as therapeutic products in countries around the world, which opens the ability for international pharmacies and healthcare providers to distribute cannabis products to patients,” added Dr. Titus. “This is yet another example of the international trend of acceptance of CBD for therapeutic use, and we are continually encouraged by the decisions of governments and regulators to permit use of cannabis and CBD products for patients suffering from multiple indications – especially where conventional medicine has had modest or limited effects.” Paraguay’s official registration of Medical Marijuana, Inc.’s CBD hemp oil products marks the first country that has registered and approved the Company’s products as medicinal products. Currently, Medical Marijuana, Inc.’s CBD hemp oil...

Read More

Puration Announces Patented Cannabis Extraction Spinoff and Dividend Plan to Optimize Shareholder Value

DALLAS, January 4, 2018 /PRNewswire/ — Puration, Inc. (PURA) today announced a spinoff and dividend strategy to optimize shareholder value. Puration is the sole licensee to U.S. Patent No. 9,199,960, entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” The license permits Puration to produce cannabis extracts for infusion into recreational, fitness wellness, alternative medicine and beauty products. Management found the ideal first application of the extraction technology in the introduction of its own cannabis infused beverage. Last year, the company launched EVERx CBD Infused Sports Water which has since become a leading brand name in the CBD infused marketplace and one of the only CBD infused products in the sports nutrition marketplace. Puration recently announced plans to launch new cannabis infused beverage lines into Canada’s legal $8 billion market in addition to announcing plans to open a cannabis extraction facility into California’s legal $10 billion market. Puration’s extraction capacity is being structured into a new subsidiary in a first step to unlock shareholder value by delineating between the company’s patented extraction business and cannabis infused beverage business. The next step will be to spinoff the cannabis extraction subsidiary in conjunction with a Regulation Crowdfunding transaction to capitalize the new independently listed company. The spinoff plan includes a dividend distribution of stock in the new independently listed company to shareholders of Puration. Management expects the...

Read More

Medical Marijuana, Inc. Announces Promotion of Subsidiary HempMeds® Mexico President Raul Elizalde to HempMeds® President, Latin America

SAN DIEGO, Jan. 4, 2018 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, today announced that Raul Elizalde, President of subsidiary HempMeds® Mexico, has been promoted to President, Latin America for the company. Elizalde, who joined Medical Marijuana, Inc. and HempMeds® Mexico in June 2017, was an active medical cannabis advocate prior to joining the Company because of his fight to gain access to CBD hemp oil for his daughter Grace, who suffers from epilepsy. Elizalde’s fight led to the legalization of medical cannabis in Mexico. “We are proud of Raul’s many accomplishments over the past six months and we felt that it was time to give him more responsibility as our global operations continue to rapidly expand,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Since joining our organization, Raul has not only helped us grow our thriving Mexico market, but has also been a global voice for the Company to spread awareness regarding why CBD should be considered a supplement that can provide therapeutic benefits to people around the world.” “I’m honored to be a part of the leading cannabis company and look forward to aggressive expansion of our company throughout Latin America,” said HempMeds® President, Latin America, Raul Elizalde. In Nov. 2017, Elizalde was invited to speak to the World Health Organization at the Expert Committee on Drug Dependence Conference in...

Read More

Canbiola, Inc. (CANB) Announces “2017 Review – Update to Shareholders”

HICKSVILLE, NY / ACCESSWIRE / January 3, 2018 / Canbiola, Inc. (OTC PINK: CANB) is happy to provide this update to shareholders and review major events and accomplishments in 2017. Dear Shareholder, 2017 was a transition year as we transformed the company from a technology/software company to a company participating in the growing cannabis industry, with a focus on selling and developing products containing Cannabidiol (CBD) derived from industrial hemp. Here’s an overview of our proud accomplishments for 2017: Medical Advisory Board and Distributors: We added a number of medical professionals to our Advisory Board in addition to entering into distribution agreements with each. Read below our specific announcements on the five medical professionals added in 2017: Dr. Robert A. Kornfeld Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor Dr. John P. Salerno Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor Dr. Patrick M. Fratellone Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor Dr. Harry Benisatto joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor Canbiola, Inc. (CANB) Announces Addition of Smita Ohri M.D. as Medical Advisor Manufacturing: We can proudly announce today that in the last quarter of 2017 we established a manufacturing agreement with a 3rd party manufacturer in the U.S. whereby we will be able to directly manufacture at manufacturers cost and white-label others’ products with no up-front fees due from the company....

Read More
  • 1
  • 2